Rhythm director sells 37K shares after option exercise
Rhythm Pharmaceuticals director Lynn A. Tetreault reported an exercise-and-sell transaction in company stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Rhythm Pharmaceuticals director Lynn A. Tetreault reported an exercise-and-sell transaction in company stock. On June 22, 2026, she exercised stock options to acquire 37,000 shares of common stock at $28.27 per share and sold 37,000 shares in open-market transactions at a weighted average price of $100.3215 per share. The sales were executed under a Rule 10b5-1 instruction adopted on December 15, 2025. Following these transactions, she directly holds 7,000 shares of common stock.
Insider Trade Summary 10b5-1
Exercise and Sale: 37,000 shares ($2.67M approx. pre-tax spread)
Exercise and Sale
3 txns
Insider
TETRAULT LYNN A.
Role
Director
Sold
37,000 shs ($3.71M)
Approx. gross sale proceeds
$3.71M
Approx. exercise cost
$1.05M
Approx. pre-tax spread
$2.67M
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (right to buy) | 37,000 | $0.00 | $0.00 |
| Exercise | Common Stock | 37,000 | $28.27 | $1.05M |
| Sale | Common Stock | 37,000 | $100.3215 | $3.71M |
Holdings After Transaction:
Stock Option (right to buy) — 0 contracts (Direct);
Common Stock — 7,000 shares (Direct)
Footnotes (3)
- F1. The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted on December 15, 2025.
- F2. The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $100.00 to $100.91. The Reporting Person undertakes to provide upon request the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
- F3. The option is fully vested and exercisable.
Key Figures
Shares sold: 37,000 shares
Weighted average sale price: $100.3215 per share
Shares acquired via option exercise: 37,000 shares
+4 more
7 metrics
Shares sold
37,000 shares
Common stock sold on June 22, 2026
Weighted average sale price
$100.3215 per share
Open-market sales on June 22, 2026
Shares acquired via option exercise
37,000 shares
Common stock from option exercise on June 22, 2026
Option exercise price
$28.27 per share
Stock option (right to buy) terms
Shares held after transaction
7,000 shares
Direct common stock ownership following June 22, 2026 trades
Option expiration date
December 8, 2030
Exercised stock option grant term
Exercise shares summary
37,000 shares
Total derivative shares exercised as reported
Key Terms
Rule 10b5-1, weighted average price, Stock Option (right to buy), Exercise or conversion of derivative security, +1 more
5 terms
Rule 10b5-1 regulatory
"The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted on December 15, 2025."
Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.
weighted average price financial
"The price reported is a weighted average price. The securities were sold in multiple transactions..."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Stock Option (right to buy) financial
"Stock Option (right to buy) ... underlying security title: Common Stock"
Exercise or conversion of derivative security financial
"transaction_code_description: Exercise or conversion of derivative security"
open-market sale financial
"transaction_action: open-market sale"
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did RYTM director Lynn A. Tetreault report?
Lynn A. Tetreault reported exercising stock options for 37,000 shares of Rhythm Pharmaceuticals common stock and selling 37,000 shares in open-market transactions on June 22, 2026. These moves are disclosed as a combined exercise-and-sell pattern in the Form 4 filing.
What stock options did Lynn A. Tetreault exercise according to the Form 4 for RYTM?
She exercised a stock option covering 37,000 shares of Rhythm Pharmaceuticals common stock at an exercise price of $28.27 per share. The option, described as fully vested and exercisable, related to a grant expiring on December 8, 2030, and was fully exercised in this transaction.
Does Lynn A. Tetreault retain any options after the reported RYTM transactions?
For the reported option, the Form 4 shows 37,000 derivative shares exercised and zero derivative shares remaining following the transaction. This indicates that the specific stock option described in the filing was fully exercised, leaving no remaining balance from that grant.
AI-generated analysis. How Rhea-AI works. Not financial advice.
